Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
85 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
Bendamustine
|
Treanda
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. F:IV Indications: Lymphoma, CLL Toxicities: Myelosuppression GI toxicity (vomiting) |
|
|
Busulfan
|
Myleran
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. F:IV, PO Indications: CML Toxicities: Myelosuppression GI toxicity (nausea, vomiting, diarrhea) Hepatotoxicity (veno-occlusive disease)-high dose CNS toxicity (seizure)-high dose Misc:rapid and complete oral absorption |
|
|
Carboplatin
|
Paraplatin
|
ALKYLATING AGENT
Platinum Complex MOA: activated by aquation intracellularly (low Cl- concentration)-->react with DNA forming intrastand (favored) and interstrand cross-linked (adducts), N7 of guanine as the primary target, DNA adducts inhibit DNA replication and transcription leading to breaks and miscoding-->apoptosis Indications: lung, lymphoma, ovarian F: IV Toxicities: Myelosuppression- more severe Other toxicities less severe than cisplatin Misc: NOT cell cycle specific, NO aluminum needles or equipment preparing or administering all platinum-containing drugs, dose reduction for renal impairment |
|
|
Chlorambucil
|
Leukeran
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. Indications: CLL F: PO Toxicities: Myelosuppression Secondary malignancy (leukemia) |
|
|
Cisplatin
|
Platinol-AQ
|
ALKYLATING AGENT
Platinum Complex MOA: activated by aquation intracellularly (low Cl- concentration)-->react with DNA forming intrastand (favored) and interstrand cross-linked (adducts), N7 of guanine as the primary target, DNA adducts inhibit DNA replication and transcription leading to breaks and miscoding-->apoptosis Indications:ovarian, testicular, lung, melanoma F:IV Toxicities: Nephrotoxicity, alleviated by chloride diuresis and amifostine (ETHYOL®) Neurotoxicity (peripheral neuropathy) Ototoxicity GI toxicity (severe vomiting and nausea), alleviated by aprepritant(EMEND®), dexamethasone and 5-HT3 antagonists Myelosuppression (mild to moderate)- mild compared to other agents and other toxicities Misc: NOT cell cycle specific, NO aluminum needles or equipment preparing or administering all platinum-containing drugs, mainly urine excretion |
|
|
Cyclophosphamide
|
Cytoxan, Neosar
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. Indications: Breast, ALL, CLL, Lung, Lymphoma F: PO, IV Toxicities: Myelosuppression (severe) GI toxicity (nausea, vomiting) Hemorrhagic cystitis-->due to accumulation of acrelein in the bladder , counteracted by mesna and diuresis (Mesna congregates w/acrelein--> reduce bladder toxicity) Cardiotoxicity (high doses) Secondary malignancy Misc: Phosphoramide mustard--> active metabolite--> anti-tumor effects |
|
|
Dacarbazine
|
DTIC-Dome
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. F:IV Indications: Lymphoma Toxicities: Myelosuppression GI toxicity (nausea, vomiting) |
|
|
Ifosfamide
|
Ifex
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. Indications: Lymphoma F: IV Toxicities: myelosuppression (more severe than CyPhos) hemorrhagic cystitis, alleviated by mesna and diuresis CNS toxicity (hallucination, coma) GI toxicity (nausea, vomiting) Misc: Much slower activation in the body, More lipophilic crosses BBB, metabolized by CYP3A4 to active form |
|
|
Mechlorethamine
|
Mustargen
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. Indications: Lymphoma F: IV Toxicities: Myelosuppression GI toxicity (nausea, vomiting) Misc: rapid iv injection (very unstable), chemical degradation (hydrolysis, deamination) in water and body fluids within minutes |
|
|
Oxaliplatin
|
Eloxatin
|
ALKYLATING AGENT
Platinum Complex MOA: activated by aquation intracellularly (low Cl- concentration)-->react with DNA forming intrastand (favored) and interstrand cross-linked (adducts), N7 of guanine as the primary target, DNA adducts inhibit DNA replication and transcription leading to breaks and miscoding-->apoptosis Indications: colorectal, gastric F: IV Toxicities: Peripheral neuropathy- most severe GI toxicity (diarrhea, stomatitis, nausea, vomiting) myelosuppression (mild) Misc: NOT cell cycle specific, NO aluminum needles or equipment preparing or administering all platinum-containing drugs, DON’T use any chloride -containing solutions to reconstitute |
|
|
Procarbazine
|
Matulane
|
ALKYLATING AGENT
Nitrogen Mustard MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains. F: PO Indication: Lymphoma Toxicities: Myelosuppression GI toxicity (N/V) Secondary malignancy Misc: rapid and complete oral absorption |
|
|
5-Fluorouracil
|
5-FU, Adrucil, Efudex
|
ANTI-METABOLITE AGENT
Pyrimidine Antagonists MOA: incorporated into both DNA and RNA, blocks thymidylate synthesis (major) by inhibiting thymidylate synthase F:IV Indications: colorectal, breast Toxicities: Myelosuppression-major GI toxicity (nausea, vomiting, stomatitis, diarrhea) Hand-foot syndrome (palmar-plantar erythrodysesthesia) Misc: co-administration of leucovorin to enhance efficacy |
|
|
Azacitidine
|
Vidaza
|
ANTI-METABOLITE AGENT
Pyrimidine Antagonists MOA: Incorporates into DNA and inhibits methyltransferase, causing demethylation in DNA Indications: AML F: IV or SQ Toxicities: Myelosuppression Renal toxicity GI toxicity |
|
|
6-Mercaptopurine
|
Purinethol
|
ANTI-METABOLITE AGENT
Purine Analog MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA Indication:ALL F: PO Toxicities: Myelosuppression- dose limiting Hepatotoxicity GI toxicity (nausea, vomiting, mucositis, stomatitis) Hyperuricemia, alleviated by allopurinol which inhibits xanthine oxidase to reduce the accumulation of uric acid , dose reduction by 75% Misc: first pass metabolism by xanthine oxidase (to uric acid), dose reduction for renal impairment |
|
|
Capecitabine
|
Xeloda
|
ANTI-METABOLITE AGENT
Pyrimidine Antagonists MOA: (Prodrug of 5-FU) incorporated into both DNA and RNA, blocks thymidylate synthesis (major) by inhibiting thymidylate synthase Indications: colorectal, breast F: PO Toxicities: GI toxicity (diarrhea, vomiting, nausea)- most severe b/c oral Hand-foot syndrome Myelosuppression Misc: dose reduction for renal impairment, Tumor specificity due to due high expression of thymidine phosphorylase in tumors and not in normal tissue= advantage over 5-FU |
|
|
Cladribine
|
Leustatin
|
ANTI-METABOLITE AGENT
Purine Analog MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA Indication: CLL, lymphoma F: IV Toxicities: Myelosuppression GI toxicity (nausea, vomiting) CNS toxicity (fever, chills) Renal toxicity |
|
|
Clofarabine
|
Clolar
|
ANTI-METABOLITE AGENT
Purine Analog MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA Indications: ALL F:IV Toxicities: Myelosuppression GI toxicity (nausea, vomiting, diarrhea) Capillary leak syndrome/systemic inflammatory response syndrome (SIRS) (vascular tone loss and extravasation of plasma fluids and proteins)=pain Hepatotoxicity |
|
|
Cytarabine
|
Ara-C, Cytosar-U
|
ANTI-METABOLITE AGENT
Pyrimidine Antagonists MOA: ara-CTP competes with dCTP for DNA incorporation, incorporated ara-CMP residues inhibit DNA polymerase, causes terminal differentiation of leukemic cells Indications: AML, ALL F: IV, IT Toxicities: Myelosuppression GI toxicity (diarrhea, mucositis, nausea, vomiting) CNS toxicity -high dose or intrathecal Misc: susceptible to cytidine deaminase(short t1/2), DEPOCYT: intrathecal liposomal formulation for sustained release in CSF (less CNS toxicity) |
|
|
Decitabine
|
Dacogen
|
ANTI-METABOLITE AGENT
Pyrimidine Antagonists MOA: incorporates into DNA and inhibits methyltransferase, causing demethylation in DNA Indication: AML F: IV Toxicities: Myelosuppression GI toxicity (nausea, vomiting, diarrhea) Misc: rapid deamination |
|
|
Fludarabine
|
Fludara
|
ANTI-METABOLITE AGENT
Purine Analog (arabinoside, adenosine-analog) MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA Indication: AML, CLL F: IV, PO Toxicities: Autoimmune effects (hemolytic anemia) Myelosuppression GI toxicity (nausea, vomiting, diarrhea) CNS toxicity (chills, blindness, coma, seizure) Misc: dose reduction for renal impairment, adenosine deaminase- resistant due to presence of F at R1 |
|
|
Gemcitabine
|
Gemzar
|
ANTI-METABOLITE AGENT
Pyrimidine Antagonists MOA: (tri-phosphorylated in vivo) dFdCTP competes with dCTP for DNA incorporation, inhibitor of DNA polymerase, dFdCDP inhibits ribonucleotide reductase Indications:breast, lung, pancreas, ovarian F: IV Toxicities(mild compared to others): Myelosuppression GI toxicity (nausea, vomiting, diarrhea) Hepatotoxicity Misc:extended infusion time increases dFdCTP formation |
|
|
Hydroxyurea
|
Hydrea
|
ANTI-METABOLITE AGENT
MOA: inhibits ribonucleotide reductase--> block biosynthesis of DNA Indications: CML, Melanoma F: PO Toxicities: Myelosuppression Cutaneous vasculitic toxicity Secondary malignancy (leukemia) GI toxicity (stomatitis, diarrhea) Misc: majority eliminated in the urine= dose reduction for renal impairment |
|
|
Methotrexate
|
Folex, Rheumatrex
|
ANTI-METABOLITE AGENT
Folic Acid analog MOA: dihydrofolate reductase ( DHFR ) inhibitor, MTX-PG is an inhibitor of DHFR, thymidylate synthase and de novo purine synthesis. Indications: ALL, breast, lymphoma F: IV Toxicities: Myelosuppression- dose limiting GI toxicity (nausea, vomiting, stomatitis) Nephrotoxicity (acute renal failure) Misc: dose reduction for renal impairment, toxicities rescued by leucovorin (folinic acid, N 5-formyl FH4), a reduced folate coenzyme. |
|
|
Nelarabine
|
Arranon
|
ANTI-METABOLITE AGENT
Purine Analog MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA Indications: ALL, lymphoma F: IV Toxicities: Myelosuppression Neurotoxicity (seizure, peripheral neuropathy) GI toxicity (nausea, diarrhea, vomiting) Misc: hepatic metabolism to form ara-G (active form) |
|
|
Pemetrexed
|
Alimta
|
ANTI-METABOLITE AGENT
Folic Acid analog MOA: dihydrofolate reductase ( DHFR ) inhibitor, more potent inhibitor of de novo purine synthesis (main mech) Indications: lung, breast, pancreas, renal, head & neck F:IV Toxcities: myelosuppression GI toxicity (nausea, vomiting, stomatitis, diarrhea) nephrotoxicty dermotogical reactions Misc: dose reduction for renal impairment,better transported into tumor cells than MTX |
|
|
Pentostatin
|
Nipent
|
ANTI-METABOLITE AGENT
Purine Analog MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA Indications: CLL, lymphoma F: IV Toxicities: GI toxicity (N/V, diarrhea, stomatitis) myelosuppression |
|
|
Irinotecan
|
Camptosar, CPT-11
|
TOPOISOMERASE I INHIBITOR
Camptothecin Analog MOA: The flat ring systems intercalate DNA at the site of cleavage, Bind and stabalize DNA-topoisomerase I “cleavable complex”, Inhibit the religation of single- stranded breaks in DNA, Cause irreversible DNA break during DNA replication, leading to apoptosis. Indication: lung, colorectal, cervical, ovarian, gastric, brain F:IV in polysorbate 80 Toxicities: Diarrhea- most sig Myelosuppression Hypersensitivity reactions- caused by polysorbate 80 (pretreat w/dexamethasone and antihistamines) Misc: metabolized by hepatic carboxylesterase to SN-38 (active), SN-38 is less hydrolyzed due to high plasma protein binding, dose reduction for hepatic impairment |
|
|
Topotecan
|
Hycamtin
|
TOPOISOMERASE I INHIBITOR
Camptothecin Analog MOA: The flat ring systems intercalate DNA at the site of cleavage, Bind and stabalize DNA-topoisomerase I “cleavable complex”, Inhibit the religation of single- stranded breaks in DNA, Cause irreversible DNA break during DNA replication, leading to apoptosis. Indication: lung, ovarian F:IV Toxicities: Myelosuppression GI toxicity (diarrhea, nausea, vomiting) Misc: 5 fused ring structure is signature for these compounds,spontaneous hydrolysis in whole blood forms less active metabolite= main metabolic pathway, dose reduction for renal impairment |
|
|
Daunorubicin
|
Cerubidine
|
TOPOISOMERASE II INHIBITOR
Anthracycline MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis Indications: AML, ALL F:IV Toxicities: Myelosuppression Cardiotoxicity Vesicant GI toxicity (nausea, vomiting, stomatitis) Misc: hepatic metabolism (active metabolite), red-colored urine, dose reduction for renal impairment |
|
|
Doxorubicin
|
Adriamycin
|
TOPOISOMERASE II INHIBITOR
Anthracycline MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis Indications: breast, ALL, lung, lymphoma, ovarian F: IV Toxicities: Myelosuppression- dose limiting Cardiotoxicity (avoid combination with cyclophosphamide, other anthracyclines or herceptin) Counteracted by concomitant use of dexrazoxane Potent vesicant- causes pain in surrounding tissue GI toxicity (nausea, vomiting, ulceration) Secondary malignancy (AML) Misc: dose reduction for hepatic impairment, rapid uptake in heart, kidney, lung, liver and spleen |
|
|
Epirubicin
|
Ellence
|
TOPOISOMERASE II INHIBITOR
Anthracycline MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis Indications: BREAST, cervical, gastric F: IV Toxicities: myelosuppression cardiotoxicity Vesicant GI toxicities (nausea, vomiting, diarrhea) Secondary malignancy (AML) Misc: dose reduction for hepatic impairment, dose reduction for renal impairment, can cause red urine |
|
|
Etoposide
|
VP-16, Vepesid
|
TOPOISOMERASE II INHIBITOR
Epipodophyllotoxin MOA: forms a ternary complex with topoisomerase II and DNA causes double-stranded DNA breaks, most sensitive in cells during S and G2 phases Indications: lung, lymphoma, testicular F: IV Toxicities: Myelosuppression GI toxicities (nausea, vomiting, diarrhea) Hepatotoxicity Hypersensitivity Misc: dose reduction for renal impairment, polysorbate 80 as vehicle |
|
|
Idarubicin
|
Idamycin PFS
|
TOPOISOMERASE II INHIBITOR
Anthracycline MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis Indications: AML, ALL F: IV Toxicities: Myelosuppression Cardiotoxicity Vesicant GI toxicity (nausea, vomiting, diarrhea) Misc: dose reduction for hepatic impairment |
|
|
Mitoxantrone
|
Novantrone
|
TOPOISOMERASE II INHIBITOR
Anthracycline MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis Indications: prostate, lymphoma F: IV Toxicities: Myelosuppression Less cardiotoxicity and other toxicities than true anthracyclines GI toxicity (nausea, vomiting, diarrhea) Vesicant secondary malignancy (AML) Misc: Doesn’t have glycoside like other anthracyclines |
|
|
Teniposide
|
Vumon
|
TOPOISOMERASE II INHIBITOR
Epipodophyllotoxin MOA: forms a ternary complex with topoisomerase II and DNA causes double-stranded DNA breaks, most sensitive in cells during S and G2 phases Indications: lymphoma, lung, pediatric ALL F: IV Toxicities: Myelosuppression Hypersensitivity reactions GI toxicities (nausea, vomiting) Misc: Cremophor EL as vehicle |
|
|
Cabazitaxel
|
Jevtana
|
MICROTUBULE TARGETING AGENT
|
|
|
Docetaxel
|
Taxotere
|
MICROTUBULE TARGETING AGENT
|
|
|
Eribulin
|
Halaven
|
MICROTUBULE TARGETING AGENT
|
|
|
Estramustine
|
Emyct
|
MICROTUBULE TARGETING AGENT
|
|
|
Ixabepilone
|
Ixempra
|
MICROTUBULE TARGETING AGENT
|
|
|
Paclitaxel
|
Taxol
|
MICROTUBULE TARGETING AGENT
|
|
|
Paclitaxel-protein bound
|
Abraxane
|
MICROTUBULE TARGETING AGENT
|
|
|
Vinblastine
|
Velban
|
MICROTUBULE TARGETING AGENT
|
|
|
Vincristine
|
Oncovin, Vincasar
|
MICROTUBULE TARGETING AGENT
|
|
|
Vindesine
|
Eldisine
|
MICROTUBULE TARGETING AGENT
|
|
|
Vinorelbine
|
Navelbine
|
MICROTUBULE TARGETING AGENT
|
|
|
Erlotinib
|
Tarceva
|
TYROSINE KINASE INHIBITOR
|
|
|
Dasatinib
|
Sprycel
|
TYROSINE KINASE INHIBITOR
|
|
|
Gefitinib
|
Iressa
|
TYROSINE KINASE INHIBITOR
|
|
|
Imatinib
|
Gleevec
|
TYROSINE KINASE INHIBITOR
|
|
|
Lapatinib
|
Tykerb
|
TYROSINE KINASE INHIBITOR
|
|
|
Nilotinib
|
Tasigna
|
TYROSINE KINASE INHIBITOR
|
|
|
Vemurafenib
|
Zelboraf
|
TYROSINE KINASE INHIBITOR
|
|
|
Crizotinib
|
Xalkori
|
TYROSINE KINASE INHIBITOR
|
|
|
All-trans retinoic acid
|
Vesanoid, ATRA
|
DIFFERENTIATION AGENT
MOA: promotes the degradation of PML-RAR-a fusion protein, displaces co-repressors of differentiation Indications: AML (APL) F: PO Toxicities: APL differentiation syndrome (retinoic acid-APL syndrome): fever, weight gain, pulmonary infiltrates, pleural or pericardial effusion, multi-organ failure Leukocytosis (opposite of myelosuppression) Hepatotoxicity Cardiovascular toxicity (edema, thrombosis) GI toxicity (nausea, vomiting, diarrhea, hemorrhage) |
|
|
Arsenic trioxide
|
Trisenox
|
DIFFERENTIATION AGENT
MOA: promotes the degradation of PML-RAR-a fusion protein, generates free radicals and inhibits angiogenesis Indications: AML (APL) F: IV Toxicities: APL differentiation syndrome Leukocytosis Cardiotoxicity (QT prolongation)- due to metal moiety Electrolyte imbalance GI toxicity (nausea, vomiting, diarrhea) |
|
|
Bortezomib
|
Velcade
|
Misc Agent
MOA: 26S proteosome inhibitor, causing inactivation of NF-kB Indications: multiple myeloma, lymphoma F: IV or SQ Toxicities: Peripheral neuropathy Myelosuppression GI toxicity (nausea, vomiting, diarrhea, constipation) Misc: dose reduction for hepatic impairment |
|
|
Thalidomide
|
Thalomid
|
Misc Agent
MOA: (unclear) G1 arrest, apoptosis, inhibits cell adhesion, decreases angiogenesis, increases NK cell activity Indications: multiple myeloma F:PO Toxicities: Severe birth defect, teratogen Myelosuppression Deep vein thrombosis and pulmonary embolism neurotoxicity (peripheral neuropathy , sedation, seizure) GI toxicity (constipation, nausea) |
|
|
Lenalidomide
|
Revlimid
|
Misc agent
MOA: (unclear) G1 arrest, apoptosis, inhibits cell adhesion, decreases angiogenesis, increases NK cell activity Indications: multiple myeloma F: PO Toxicities: Myelosuppression-serious Other toxicities less severe than thalidomide |
|
|
L-asparaginase
|
Elpsar
|
Misc agent
MOA: deprives tumor cells that relay on exogenous L-asparagine, inhibits protein synthesis and causes cell death Indications: ALL F: IV or IM Toxicities: Hypersensitivity reactions Hepatotoxicity Inhibition of protein synthesis, leading to: hyperglycemia (dec insulin) clotting abnormalities (dec clotting factors) hypertrigleridemia (dec lipoprotein), pancreatitis |
|
|
Bleomycin
|
Blenoxane
|
Misc agent
MOA: cause single- and double-stranded DNA breaks Indications: lymphoma, melanoma, testicular F: IV, IM, or SQ Toxicities: Pulmonary fibrosis- dose dependant/limiting Cutaneous reactions (hyperpigmentation, erythema, ulceration) Hypersensitivity reactions Hepatotoxicity Misc: dose reduction for renal impairment, Maximum cumulative lifetime dose: 400 unit*** |
|
|
Abarelix
|
Plenaxis
|
ANTI-HORMONAL AGENT
|
|
|
Anastrazole
|
Arimidex
|
ANTI-HORMONAL AGENT
|
|
|
Bicalutamide
|
Casodex
|
ANTI-HORMONAL AGENT
|
|
|
Exemestane
|
Aromasin
|
ANTI-HORMONAL AGENT
|
|
|
Flutamide
|
Eulexin
|
ANTI-HORMONAL AGENT
|
|
|
Fulvestrant
|
Faslodex
|
ANTI-HORMONAL AGENT
Selective estrogen-receptor downregulator (SERD), pure anti-estrogen MOA: inhibit ER dimerization and increase its degradation Indications: ER-positive breast cancer, postmenopausal F: IM Toxicities: Hot flashes, nausea, vomiting, headache Misc: effective in tamoxifen-resistant cells |
|
|
Goserelin
|
Zoladex
|
ANTI-HORMONAL AGENT
LHRH Agonist MOA: Suppression of ovarian due to decreased levels of LH and FSH with subsequent decrease in estrogen in women |
|
|
Letrozole
|
Femara
|
ANTI-HORMONAL AGENT
|
|
|
Leuprolide acetate
|
Lupron Depot, Viadur, Eligard
|
ANTI-HORMONAL AGENT
|
|
|
Megestrol Acetate
|
Megace
|
ANTI-HORMONAL AGENT
|
|
|
Nilutamide
|
Nilandron
|
ANTI-HORMONAL AGENT
|
|
|
Raloxifene
|
Evista
|
ANTI-HORMONAL AGENT
Selective Estrogen Receptor Modulators (SERMs) MOA: downregulate ER (anti-estrogenic in breast cells, estrogenic in uterus (endometric cells)) Indications: ER+ breast cancer F: po Toxicities: Increased risk for stroke in patients with coronary heart disease Increased risk for thromboembolic disease Hot flashes, edema, vaginal bleeding, vomiting Misc: extensive first-pass effect |
|
|
Tamoxifen
|
Nolvadex
|
ANTI-HORMONAL AGENT
Selective Estrogen Receptor Modulators (SERMs) MOA: downregulate ER (anti-estrogenic in breast cells, estrogenic in uterus (endometric cells)) Indications: ER+ breast cancer F: po Toxicities: Increased risk for uterine (endometric) cancer Thromboembolic events (stroke, pulmonary) Occular toxicity Hepatotoxicity Decreased bone mineral density in premanopausal patients Hot flashes, edema, vaginal bleeding, nausea |
|
|
Toremifene
|
Fareston
|
ANTI-HORMONAL AGENT
Selective Estrogen Receptor Modulators (SERMs) MOA: downregulate ER (anti-estrogenic in breast cells, estrogenic in uterus (endometric cells)) Indications: ER+ breast cancer (postmenopausal) F: po Toxicities: Hot flashes, nausea, vaginal discharge |
|
|
Degarelix
|
Firmagon
|
ANTI-HORMONAL AGENT
|
|
|
Alemtuzumab
|
Campath
|
MONOCLONAL ANTIBODY
|
|
|
Bevacizumab
|
Avastin
|
MONOCLONAL ANTIBODY
|
|
|
Cetuximab
|
Erbitux
|
MONOCLONAL ANTIBODY
|
|
|
Ipilimumab
|
Yervoy
|
MONOCLONAL ANTIBODY
|
|
|
Pantimumab
|
Vectibix
|
MONOCLONAL ANTIBODY
|
|
|
Rituximab
|
Rituxan
|
MONOCLONAL ANTIBODY
|
|
|
Trastuzumab
|
Herceptin
|
MONOCLONAL ANTIBODY
|
|
|
Brentuximab Vedotin
|
Adcetris
|
MONOCLONAL ANTIBODY
|
|
|
Ofatumumab
|
Arzerra
|
MONOCLONAL ANTIBODY
|
